ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
September 8, 2014 7:00 AM UTC
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $2.63 (11%) to $26.61 on Tuesday after FDA granted breakthrough therapy designation to Nuplazid pimavanserin to treat Parkinson's disease psychosis. The compound has completed a Phase III trial in the indication, with an NDA submission slated for year end.
Acadia finished the week up $2.98 (12%) to $26.96...